Active substance
Results for the substance fedratinib
1 result
About this active substance
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor used for the treatment of primary myelofibrosis and secondary myelofibrosis. It works by inhibiting JAK-STAT signaling, thereby reducing abnormal cell proliferation.
The medication is taken orally, once daily, as directed by a doctor. It is important to monitor liver function and thiamine levels during treatment.
Side effects may include nausea, diarrhea, anemia, or thrombocytopenia. In rare cases, Wernicke's encephalopathy or other severe reactions may occur.
Fedratinib is not recommended for patients with hypersensitivity to this medication or severe hepatic impairment.
The medication is taken orally, once daily, as directed by a doctor. It is important to monitor liver function and thiamine levels during treatment.
Side effects may include nausea, diarrhea, anemia, or thrombocytopenia. In rare cases, Wernicke's encephalopathy or other severe reactions may occur.
Fedratinib is not recommended for patients with hypersensitivity to this medication or severe hepatic impairment.